These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37778239)

  • 41. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
    Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
    Elife; 2020 Sep; 9():. PubMed ID: 32897190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    Depeille P; Henricks LM; van de Ven RA; Lemmens E; Wang CY; Matli M; Werb Z; Haigis KM; Donner D; Warren R; Roose JP
    Nat Cell Biol; 2015 Jun; 17(6):804-15. PubMed ID: 26005835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.
    Evelyn CR; Duan X; Biesiada J; Seibel WL; Meller J; Zheng Y
    Chem Biol; 2014 Dec; 21(12):1618-28. PubMed ID: 25455859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor.
    Li A; Li X; Zou J; Zhuo X; Chen S; Chai X; Gai C; Xu W; Zhao Q; Zou Y
    Bioorg Chem; 2023 Jun; 135():106500. PubMed ID: 37003134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer.
    Hamilton G; Stickler S; Rath B
    Explor Target Antitumor Ther; 2023; 4(5):1027-1038. PubMed ID: 38023987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural basis of the atypical activation mechanism of KRAS
    Bera AK; Lu J; Wales TE; Gondi S; Gurbani D; Nelson A; Engen JR; Westover KD
    J Biol Chem; 2019 Sep; 294(38):13964-13972. PubMed ID: 31341022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity.
    Quilliam LA; Huff SY; Rabun KM; Wei W; Park W; Broek D; Der CJ
    Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8512-6. PubMed ID: 8078913
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Cowan JR; Salyer L; Wright NT; Kinnamon DD; Amaya P; Jordan E; Bamshad MJ; Nickerson DA; Hershberger RE
    Circ Genom Precis Med; 2020 Aug; 13(4):e002892. PubMed ID: 32603605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.
    Moghadamchargari Z; Shirzadeh M; Liu C; Schrecke S; Packianathan C; Russell DH; Zhao M; Laganowsky A
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33723061
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo.
    Pang X; Cui D; Lv B; Wang CY
    J Med Chem; 2024 Jan; 67(2):1563-1579. PubMed ID: 38206836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics.
    Hamilton G; Plangger A
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1065-1074. PubMed ID: 34347509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
    De S; Dermawan JK; Stark GR
    Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11721-6. PubMed ID: 25071181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct interaction of SOS1 Ras exchange protein with the SH3 domain of phospholipase C-gamma1.
    Kim MJ; Chang JS; Park SK; Hwang JI; Ryu SH; Suh PG
    Biochemistry; 2000 Jul; 39(29):8674-82. PubMed ID: 10913276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis, and evaluation of dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitors for the treatment of cancers.
    Zeng Y; Huang C; Hou Q; Jiang W; Cheng J; Wu X
    Bioorg Chem; 2024 Dec; 153():107833. PubMed ID: 39357170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
    Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
    Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
    Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
    J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
    Kiel C; Serrano L
    Sci Signal; 2009 Jul; 2(81):ra38. PubMed ID: 19638615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic Lethal Vulnerabilities in
    Aguirre AJ; Hahn WC
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.